Opiate Substitution Treatment
"Opiate Substitution Treatment" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Medical treatment for opioid dependence using a substitute opiate such as METHADONE or BUPRENORPHINE.
| Descriptor ID |
D058850
|
| MeSH Number(s) |
E02.319.620
|
| Concept/Terms |
Opiate Substitution Treatment- Opiate Substitution Treatment
- Opiate Substitution Treatments
- Substitution Treatment, Opiate
- Substitution Treatments, Opiate
- Treatment, Opiate Substitution
- Treatments, Opiate Substitution
- Opioid Substitution Treatment
- Opioid Substitution Treatments
- Substitution Treatment, Opioid
- Substitution Treatments, Opioid
- Treatment, Opioid Substitution
- Treatments, Opioid Substitution
- Opioid Substitution Therapy
- Opioid Substitution Therapies
- Substitution Therapies, Opioid
- Substitution Therapy, Opioid
- Therapies, Opioid Substitution
- Therapy, Opioid Substitution
- Opiate Replacement Therapy
- Opiate Replacement Therapies
- Replacement Therapies, Opiate
- Replacement Therapy, Opiate
- Therapies, Opiate Replacement
- Therapy, Opiate Replacement
- Opioid Replacement Therapy
- Opioid Replacement Therapies
- Replacement Therapies, Opioid
- Replacement Therapy, Opioid
- Therapies, Opioid Replacement
- Therapy, Opioid Replacement
|
Below are MeSH descriptors whose meaning is more general than "Opiate Substitution Treatment".
Below are MeSH descriptors whose meaning is more specific than "Opiate Substitution Treatment".
This graph shows the total number of publications written about "Opiate Substitution Treatment" by people in this website by year, and whether "Opiate Substitution Treatment" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2016 | 1 | 1 | 2 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 1 | 2 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 2 | 2 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Opiate Substitution Treatment" by people in Profiles.
-
Understanding the financial barriers to treatment among individuals with opioid use disorder: a focus group study. Harm Reduct J. 2024 Dec 20; 21(1):220.
-
96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial. Int J Drug Policy. 2024 May; 127:104390.
-
Provider perceptions of systems-level barriers and facilitators to utilizing family-based treatment approaches in adolescent and young adult opioid use disorder treatment. Addict Sci Clin Pract. 2024 03 21; 19(1):20.
-
Evaluating the Association between Prenatal Care Visits and Adverse Perinatal Outcome in Pregnancies Complicated by Opioid Use Disorder. Am J Perinatol. 2024 05; 41(S 01):e2225-e2229.
-
Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder: A Review. JAMA Psychiatry. 2023 01 01; 80(1):84-92.
-
Barriers and Facilitators to DATA Waivered Providers Prescribing Buprenorphine: A Qualitative Analysis Applying the Theory of Planned Behavior. Subst Use Misuse. 2022; 57(12):1761-1771.
-
Comparing Two Databases to Identify Access to Buprenorphine Treatment for Opioid Use Disorder. J Pain Palliat Care Pharmacother. 2022 Jun; 36(2):103-111.
-
Sex-Specific Risk Factors and Health Disparity Among Hepatitis C Positive Patients Receiving Pharmacotherapy for Opioid Use Disorder: Findings From a Propensity Matched Analysis. J Addict Med. 2022 Jul-Aug 01; 16(4):e248-e256.
-
Switching pharmacies leads to gaps in medication possession in individuals treated with buprenorphine. J Am Pharm Assoc (2003). 2021 Sep-Oct; 61(5):589-595.
-
Impact of COVID-19 Related Policy Changes on Buprenorphine Dispensing in Texas. J Addict Med. 2020 12; 14(6):e372-e374.